Editorial Board

Our editorial board is comprised of clinical and pharmacological experts, organized primarily by disease focus. Most disease types now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].

Editor-in-Chief

Peter C. Yang, MD Boston, MA Hem_Onc

Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts.

Deputy Editor

Jeremy L. Warner, MD, MS, FAMIA Vanderbilt University Nashville, TN Hemoncwarner LinkedIn

Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University.

Associate Editors

Clinical Pharmacology
	Donna Rivera, PharmD, MSc National Cancer Institute Rockville, MD	Dr. Rivera is a Scientific Project Officer in the Surveillance Informatics Branch of the Surveillance Research Program in the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI).
Evidence-based Oncology
	Bishal Gyawali, MD, PhD Queen’s University Kingston, Canada oncology_bg	Dr. Gyawali is an assistant professor in the Department of Public Health Sciences at Queen’s University, Kingston, Canada. He is an advocate of "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable.

Section Editors

Breast Oncology
	Hermina Fernandes, MD, FACP Bismarck, ND	Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the Edith Sanford Breast Center at Sanford Health. She is a clinical associate professor at the University of North Dakota.
Dermatologic Oncology
	Elizabeth Buchbinder, MD Boston, MA LinkedIn	Dr. Buchbinder is board certified in Medical Oncology; she practices at the Dana-Farber Cancer Institute. She is an instructor at Harvard Medical School.
Endocrine Oncology
	Unfilled	If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Gastrointestinal Oncology
	Neeta K. Venepalli, MD, MBA Chicago, IL	Dr. Venepalli is board certified in Medical Oncology; she practices at UI Health. She is an associate professor at the University of Illinois at Chicago.
Genitourinary Oncology
	Ali Raza Khaki, MD Seattle, WA	Dr. Khaki is a hematology/oncology fellow at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle, Washington.
Gynecologic Oncology
	Summer B. Dewdney, MD Chicago, IL	Dr. Dewdney is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at Rush Copley Medical Center. She is an assistant professor at Rush University.
Head & Neck Cancer
	Michael Gibson, MD, PhD Nashville, TN mgibson21212 LinkedIn	Dr. Gibson is board certified in Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University.
Neuro-Oncology
	Seema Nagpal, MD Palo Alto, CA	Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a clinical associate professor at Stanford University
Sarcoma
	Elizabeth J. Davis, MD Nashville, TN ejdavis25	Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center. She is an assistant professor at Vanderbilt University.
Thoracic Oncology
	Travis Osterman, DO, MS Nashville, TN TravisOsterman LinkedIn	Dr. Osterman is board certified in Medical Oncology and Clinical Informatics; he practices at Vanderbilt University Medical Center. He is an assistant professor at Vanderbilt University.
Acute Leukemias
	Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO	Dr. Schoen is board certified in Internal Medicine and board eligible in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University.
Myeloproliferative Neoplasms and Myelodysplastic Syndromes
	Sanjay R. Mohan, MD, MSCI Nashville, TN	Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University.
Aggressive Lymphomas & Lymphoproliferative disorders
	Tarsheen Sethi, MD, MSCI Yale University New Haven, CT	Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University.
Indolent Lymphomas
	Sanjai Sharma, MD Visalia, CA	Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center.
Plasma Cell Dyscrasias
	Andrew J. Cowan, MD Seattle, WA andrewcowanmd LinkedIn	Dr. Cowan is board certified in Hematology and Medical Oncology; he practices at the Seattle Cancer Care Alliance. He is an assistant professor at the University of Washington.
T-cell and NK-cell neoplasms
	Bhagirathbhai Dholaria, MBBS Nashville, TN	Dr. Dholaria is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University.
Histiocyte Disorders
	Ronald S. Go, MD Rochester, MN	Dr. Go is board certified in Hematology and Medical Oncology; he practices at the Mayo Clinic, where he is an associate professor.
Immuno-Oncology
	Meghan J. Mooradian, MD Boston, MA LinkedIn	Dr. Mooradian is board certified in Medical Oncology; she practices at Massachusetts General Hospital. She is an instructor at Harvard Medical School.
Pediatric Oncology
	Wayne H. Liang, MD, MS Birmingham, AL WayneLiangMD LinkedIn	Dr. Liang is board certified in Pediatrics and Pediatric Hematology-Oncology; he practices at Children's of Alabama. He is an assistant professor at UAB.
Transplant
	Talal Hilal, MD University of Mississippi Jackson, MS THilalMD	Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at University of Mississippi Medical Center. He is an assistant professor at the University of Mississippi.
Classical Hematology
	Benjamin Tillman, MD Nashville, TN	Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University.

Page Editors

• Ivy Abraham, MD
  • Gastric cancer
  • Periampullary adenocarcinoma

• Karine A. Darbinyan, MD (Montefiore Medical Center, Bronx, NY)
  • Antiemesis

• Laura S. Graham, MD (University of Washington, Seattle, CA)
  • Prostate cancer

• Amit Kulkarni, MD (University of Minnesota, Minneapolis, MN)
  • Non-small cell lung cancer

• Eric I. Marks, MD (Boston University, Boston, MA)
  • Gastrointestinal stromal tumor

• Meghan J. Mooradian, MD (Massachusetts General Hospital, Boston, MA)
  • Immunotherapy toxicity management

• Ryan Nguyen, DO (University of Illinois at Chicago, IL)
  • Colon cancer
  • Esophageal cancer
  • Rectal cancer

• Matthew Rioth, MD, MS (University of Colorado, Aurora, CO)
  • Uveal melanoma

• Samuel M. Rubinstein, MD (University of North Carolina, Chapel Hill, NC)
  • Light-chain (AL) amyloidosis
  • Smoldering multiple myeloma

• Candice Schwartz, MD (University of Illinois at Chicago, IL)
  • Hepatocellular carcinoma
  • Pancreatic cancer

• Ari Seifter, MD (University of Illinois at Chicago, IL)
  • Anal cancer
  • Cholangiocarcinoma
  • Gallbladder cancer

• Nishi N. Shah, MD (Montefiore Medical Center, Bronx, NY)
  • Peripheral T-cell lymphoma

• Risa L. Wong, MD (University of Washington, Seattle, CA)
  • Bladder cancer

COI Disclosures

To be completed; please see our conflict of interest page for more details.

Name	Research funding	Other (honoraria, travel support, significant ownership interests, etc.)	Date of disclosure
Dr. Liang	Nothing to disclose	Nothing to disclose	Sept. 17, 2018
Dr. Tillman	Nothing to disclose	Nothing to disclose	Sept. 13, 2018
Dr. Warner	NIH; Vanderbilt University	Travel: AACR; ASCO Ownership: HemOnc.org Consulting: Westat, IBM Watson Health	September 5, 2020
Dr. Yang	Nothing to disclose	HemOnc.org; stock: Merck, Pfizer	Oct. 3, 2018